Business
HLS Therapeutics Announces Q1 2026 Financial Results
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three months ended March 31, 2026 ("Q1 2026"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
About this update from Hls Therapeutics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Q1 2026 revenue of $12.9 million, up 2% year-over-year; Vascepa net sales grew 15%, the strongest quarterly growth since Q2 2025","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash from operations of $6.4 million in Q1 2026, up 80% year-over-year; net debt reduced to $31.9 million, down 32% from Q1 2025","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"NILEMDO™ full commercial launch in April","length":40,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 financial guidance reaffirmed: revenue of $56–60 million and Adjusted EBITDA of $18.5–21 million","length":101,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":397,"olType":false},{"type":"text","content":"TORONTO, May 15, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three months ended March 31, 2026 ("Q1 2026"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.","length":437,"tagName":"p"},{"type":"text","content":"Q1 F2026 FINANCIAL HIGHLIGHTS (comparisons are to the respective 2025 period)","length":77,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Q1 2026 revenue was $12.9 million, Adjusted EBITDA was $3.5 million and cash from operations was $6.4 million, compared to $12.6 million, $3.8 million and $3.5 million, respectively.","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Vascepa net sales increased 15% to $4.8 million in Q1 2026, compared to $4.2 million.","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Vascepa unit growth was 18% in Q1 2026, reflecting sustained demand growth.","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Canada and U.S. combined net sales of Clozaril were $7.8 million in Q1 2026, compared to $8.2 million.","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Q1 2026 direct brand contribution for Clozaril was $5.6 million and the cardiovascular portfolio had a break-even direct brand contribution inclusive of NILEMDO™ launch investment.","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"Made princip...